Trials / Completed
CompletedNCT04550195
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants
A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety and Tolerability, and Pharmacokinetics (Including Food Effect, pH Effect and Japanese Bridging Study) of BMS-986337 Following Oral Administration in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986337 in healthy participants and in healthy Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986337 | Specified Dose on Specified Days |
| OTHER | BMS-986337 Placebo | Specified Dose on Specified Days |
| BIOLOGICAL | Famotidine | Specified Dose on Specified Days |
Timeline
- Start date
- 2020-09-17
- Primary completion
- 2021-03-03
- Completion
- 2021-03-03
- First posted
- 2020-09-16
- Last updated
- 2022-02-25
Locations
1 site across 1 country: Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04550195. Inclusion in this directory is not an endorsement.